14-day Premium Trial Subscription Sign Up For FreeGet Free

Jazz Pharmaceuticals plc Stock Forecast NASDAQ:JAZZ

$123.79 (1.88%)

Volume: 517k

Closed: Dec 07, 2021

Hollow Logo Score: -1.917

Jazz Pharmaceuticals plc Stock Forecast

$123.79 (1.88%)

Volume: 517k

Closed: Dec 07, 2021

Score Hollow Logo -1.917
Which way will JAZZ go? Request
Key Stats
P/E Ratio -46.42
Beta 0.93
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 26 and the stock is currently not being overbought or oversold

Jazz Pharmaceuticals plc stock price up 1.88% on Tuesday
(Updated on Dec 07, 2021)


Sell candidate since 2021-11-26 Loss -0.24%

The Jazz Pharmaceuticals plc stock price gained 1.88% on the last trading day (Tuesday, 7th Dec 2021), rising from $121.51 to $123.79. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 2.58% from a day low at $122.05 to a day high of $125.20. The price has been going up and down for this period, and there has been a -4.35% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 24 thousand more shares were traded than the day before. In total, 517 thousand shares were bought and sold for approximately $64.00 million.

The stock lies in the lower of a wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $119.30 is broken, it will firstly indicate a stronger fall rate. Given the current short-term trend, the stock is expected to fall -4.85% during the next 3 months and, with a 90% probability hold a price between $113.51 and $135.00 at the end of this 3-month period.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Tuesday, November 30, 2021, and so far it has risen 3.27%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Jazz Pharmaceuticals plc stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $132.74. On a fall, the stock will find some support from the short-term average at $121.67. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss

Jazz Pharmaceuticals plc finds support from accumulated volume at $122.41 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $3.15 between high and low, or 2.58%. For the last week, the stock has had a daily average volatility of 3.13%.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Jazz Pharmaceuticals plc stock A Buy?

Jazz Pharmaceuticals plc holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.917

Predicted Opening Price for Jazz Pharmaceuticals plc of Wednesday, December 8, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 8, 2021 Current price
$123.68 $123.79 (Overvalued)
Sell Candidate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Oct 08, 2021 "Morgan Stanley" gave "$176.00 - $174.00" rating for JAZZ. The price target was set to $138.48+1.1%.

Volatility and Risk
Daily Average Volatility: 3.13 %
Overall Risk: Very High High Medium Low Very Low
Volatility
3.13 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $133.22
Price: $123.79
Support: $122.41

JAZZ Insider Trading Show all Trades

INSIDER POWER

1.034

Last 100 transactions
Buy: 201 188 | Sell: 194 645 (Shares)
Date Action Amount Person Type
Dec 02, 2021 Sell 417 Smith Mark Douglas Ordinary Shares
Dec 02, 2021 Sell 417 Cook Jennifer E. Ordinary Shares
Dec 01, 2021 Sell 9 700 Cozadd Bruce C Non-Qualified Stock Option (right to buy)
Dec 01, 2021 Sell 2 758 Cozadd Bruce C Ordinary Shares
Dec 01, 2021 Sell 3 990 Cozadd Bruce C Ordinary Shares
Show all Insider Trades
INSIDER POWER

1.034

Last 100 transactions
Buy: 201 188 | Sell: 194 645 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 126.82 2.45 %
125.62 1.48 %
124.88 0.88 %
Current price: 123.79
Support 122.48 -1.06 %
121.73 -1.66 %
120.53 -2.63 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 136.91 10.60 %
134.50 8.65 %
133.22 7.62 %
Current price 123.79
Support 122.41 -1.11%
121.16 -2.12%
119.87 -3.17%

Click to get the best stock tips daily for free!

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in pat... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT